What is Rothmund-Thomson Syndrome

Rothmund-Thomson Syndrome (RTS) is a rare genetic disorder characterized by a distinct facial rash (poikiloderma) that begins in infancy, along with skeletal abnormalities, sparse hair, and an increased risk of developing certain cancers, particularly osteosarcoma. While the clinical presentation varies widely, individuals with Rothmund-Thomson Syndrome often require lifelong monitoring by a multidisciplinary medical team to manage dermatological and oncological risks.

What are the primary clinical features of Rothmund-Thomson Syndrome?

The hallmark of Rothmund-Thomson Syndrome is poikiloderma—a combination of redness, skin atrophy, and mottled pigmentation that typically appears on the cheeks between 3 and 6 months of age. Beyond the skin, individuals may experience:

• Skeletal defects: Small stature, absent or malformed thumbs, and radial ray anomalies.


• Dental and hair issues: Sparse scalp hair, eyelashes, or eyebrows, and delayed or missing permanent teeth.


• Ocular findings: A significant risk of juvenile cataracts, which often appear in the first few years of life.


• Cancer predisposition: A notably higher-than-average risk for osteosarcoma and squamous cell carcinoma.

How is Rothmund-Thomson Syndrome classified?

Clinicians divide Rothmund-Thomson Syndrome into two main types based on genetic mutations. Type I is associated with mutations in the ANTXR1 gene and is characterized by poikiloderma and juvenile cataracts. Type II is caused by mutations in the RECQL4 gene and typically presents with more severe skeletal abnormalities and a higher risk of osteosarcoma.

How rare is Rothmund-Thomson Syndrome?

Rothmund-Thomson Syndrome is extremely rare, with fewer than 300 cases reported in medical literature globally. It is an autosomal recessive condition, meaning an individual must inherit a mutated gene copy from both parents to manifest the disease. While there is no known geographic or ethnic bias, the rarity of the condition makes it difficult to pinpoint an exact prevalence rate.

Why is early diagnosis important for RTS patients?

Because Rothmund-Thomson Syndrome carries an increased risk of malignancy, regular screenings are vital. Early detection of skeletal issues and cataracts allows for timely intervention, significantly improving the quality of life for those living with the condition.

Next steps

• Consult with a clinical geneticist to discuss genetic testing and familial inheritance risks.


• Schedule baseline evaluations with a dermatologist, ophthalmologist, and pediatric oncologist.


• Join the DiseaseMaps.org community to connect with other families navigating the challenges of this rare diagnosis.

Medical disclaimer: This information is for educational purposes and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Rothmund-Thomson Syndrome entry.


• Orphanet: Overview of Rothmund-Thomson Syndrome (ORPHA:790).


• OMIM (Online Mendelian Inheritance in Man): Entry #268400 (RTS Type 2).


• PubMed: Clinical reviews on RECQL4-related disorders.